WO2010023686A2 - Crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4]naphthoquinone, process for the same and use for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone - Google Patents

Crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4]naphthoquinone, process for the same and use for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone Download PDF

Info

Publication number
WO2010023686A2
WO2010023686A2 PCT/IN2009/000462 IN2009000462W WO2010023686A2 WO 2010023686 A2 WO2010023686 A2 WO 2010023686A2 IN 2009000462 W IN2009000462 W IN 2009000462W WO 2010023686 A2 WO2010023686 A2 WO 2010023686A2
Authority
WO
WIPO (PCT)
Prior art keywords
naphthoquinone
chlorophenyl
cyclohexyl
chloro
hydroxy
Prior art date
Application number
PCT/IN2009/000462
Other languages
French (fr)
Other versions
WO2010023686A3 (en
Inventor
Saswata Lahiri
Jitendra Sharma
Hemraj Lande
Mounishwarachar Virupakshachar Agadi
Sreedhar Rapolu
Venkata Naga Vikas Chandra Dev Ravi
Debashish Data
Original Assignee
Matrix Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Limited filed Critical Matrix Laboratories Limited
Publication of WO2010023686A2 publication Critical patent/WO2010023686A2/en
Publication of WO2010023686A3 publication Critical patent/WO2010023686A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C07C46/10—Separation; Purification; Stabilisation; Use of additives

Definitions

  • This invention in general relates to a process for producing 2-[4-(4- chlorophenyl) cyclohexyl]-3-hydroxy-l,4-naphthoquinone (Atovaquone). More particularly the present invention provides a crystalline form of 2-chloro-3-[4-(4- chlorophenyl) cyclohexyl] [l,4]naphthoquinone, process for preparing the same and employing the same for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone.
  • Atovaquone is an antiprotozoal agent for oral administration, chemically known as trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4-naphthalenedione as represented by Formula I:
  • Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), a common parasitic lung infection of immunocompromised patients. It is not only used for the treatment of PCP, but also displays potent activity as an antimalarial agent, and has been used in the treatment of taxoplasmosis and babesiosis. Atovaquone is marketed under the brand name of MEPRON® oral suspension containing about 750mg of Atovaquone.
  • PCP Pneumocystis carinii pneumonia
  • Atovaquone and its pharmaceutically acceptable salts are first disclosed in US Patent No 5,053,432 (the '432 patent).
  • the patent further discloses a process for the preparation of trans compound of atovaquone.
  • the specific process for the preparation of atovaquone is schematically represented in scheme-I as follows:
  • the '432 patent discloses the process for the preparation of atovaquone, wherein 2-chloro-l,4-naphthoquinone of formula-II is condensed with 4-(4- chlorophenyl)cyclohexane-l-carboxylic acid of formula-Ill in the presence of silver nitrate and ammonium persulphate in a mixture of acetonitrile, sulpholane and water solvent system in the ratio of 1.0: 3.0: 8.0 to give 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4]naphthoquinone compound of formula-IV which is further subjected to hydrolysis in the presence of boiling methanol and aqueous KOH followed by recrystallization in acetonitrile to give atovaquone of compound of formula-I.
  • US Patent No 4,981,874 discloses a process for the preparation of atovaquone, wherein 2-chloro-l,4-naphthoquinone of formula-II is condensed with 4-(4-chlorophenyl)cyclohexane-l-carboxylic acid of formula-Ill in the presence of silver nitrate in a mixture of acetonitrile and water solvent system in the ratio of 5.0:6.0 to give 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone compound of formula-IV which is further subjected to hydrolysis in the presence of boiling methanol and aqueous KOH followed by recrystallization in acetonitrile to give atovaquone compound of formula-I.
  • the process for the preparation of atovaquone includes condensing 2-chloro-l,4-naphthoquinone compound of formula-II with 4-(4- chlorophenyl)cyclohexane-oxalate acid compound of formula- V in the presence of the phase transfer catalyst Adogen®464, oxidant ammonium persulphate in a mixture of dichloromethane, acetonitrile and water in the ratio of 1:1:2 to give 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4] naphthoquinone in 43% yield and an additional side product with 38% yield.
  • the additional side product formed along with the compound of formula-I in the process requires repeated crystallizations to remove the additional side product from the final product, thereby resulting in low yield at final stage.
  • a crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone wherein said crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by an X-ray powder diffraction pattern having peaks at about 7.14, 9.91, 14.45, 14.90, 16.23, 17.81, 19.93, 21.56, 25.23, 25.51, 26.74 ⁇ 0.2 ⁇ °.
  • a process for preparing crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone comprises of condensing 2- chloro-[l,4] naphthoquinone with 4-(4-chlorophenyl)-cyclohexane carboxylic acid in the presence of silver nitrate and a persulphate in a solvent mixture to give 2-Chloro- 3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein the solvent mixture comprises acetonitrile, water and sulpholane in the ratio of 1.0: 1.0: 0.1 to 0.5.
  • the process further comprises of purifying the 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone by employing a solvent to obtain pure crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone.
  • a process for preparing 2-[4-(4-chlorophenyl) cyclohexy 1] -3 -hydroxy- 1,4- naphthoquinone comprises of condensing 2-chloro-[l,4] naphthoquinone with 4-(4-chlorophenyl)-cyclohexane carboxylic acid in the presence of silver nitrate and a persulphate in a solvent mixture to give 2-Chloro-3-[4-(4- chlorophenyl) cyclohexy I][1, 4] naphthoquinone, and hydrolyzing the 2-Chloro-3-[4- (4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone in the presence of an alkali earth metal hydroxide and a solvent to give 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-
  • the solvent used in hydrolyzing the 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is mixture of water and alcohol.
  • the alcohol solvent is selected from methanol, ethanol and isopropyl alcohol, preferably methanol.
  • the process further comprises of purifying the 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone employing a solvent to obtain pure 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone.
  • the process further comprises of micronizing the pure 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone to obtain micronized 2- [4- (4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone having particle size distribution dg 0 less than 10 micrometer, preferably between 3.0 - 10 micrometer.
  • Fig. 1 shows the X-ray diffraction pattern of 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone (Atovaquone) obtained as per the present invention.
  • Fig. 2 shows the X-ray diffraction pattern of 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl] [l,4]naphthoquinone compound of formula-IV obtained as per the present invention.
  • the present invention discloses a crystalline form of 2-chloro-3-[4-(4- chlorophenyl) cyclohexyl] [l,4]naphthoquinone.
  • the crystalline form of 2-chloro-3- [4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by X-ray powder diffraction pattern.
  • the present invention describes an improved process for the preparation of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone.
  • the 2,-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is employed for the preparation of 2- [4-(4-chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone.
  • Powder X-rav Diffraction PXRDI
  • the crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone of the present invention is characterized by its X-ray powder diffraction pattern.
  • the X-ray diffraction pattern of said crystalline form of the invention was measured on PANaiytical, X'Pert PRO powder diffractometer equipped with goniometer of ⁇ / ⁇ configuration and X'Celerator detector.
  • the Cu-anode X-ray tube was operated at 40 KV and 30 mA. The experiments were conducted over the 2 ⁇ range of 2.0°-50.0°, 0.030° step size and 50 seconds step time.
  • the crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by an X-ray powder diffraction pattern as shown in Figure 2 having peaks at about 7.14, 9.91, 14.45, 14.90, 16.23, 17.81, 19.93, 21.56, 25.23, 25.51, 26.74 ⁇ 0.2 ⁇ °.
  • the improved process for the preparation of crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone of formula IV wherein the process involves condensing 2- chloro-[ 1,4] naphthoquinone of formula (III) with 4-(4-chlorophenyl)-cyclohexane carboxylic acid of formula (II) in the presence of free radical initiators and an oxidant in a solvent mixture to give crude 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4]naphthoquinone of formula (IV) as shown in the following scheme: Scheme-Ill
  • the process further comprises hydrolyzing 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4]naphthoquinone using an alkali earth metal hydroxide in presence of a suitable solvent to give 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone of formula I.
  • the free radical initiator used in the condensation reaction is selected from sodium persulphate, ammonium persulphate, more preferably sodium persulphate and the oxidant is preferably silver nitrate.
  • the solvent mixture used in the condensation of 2-chloro-[l,4]naphthoquinone of Formula-Ill with 4-(4- chlorophenyl)-cyclohexane carboxylic acid of Formula-II to obtain 2-Chloro-3-[4-(4- chlorophenyl) cyclohexyl][l,4]naphthoquinone compound of formula- IV is selected from water miscible organic solvent, water or mixtures thereof.
  • the water miscible organic solvent is selected from acetonitrile, acetone, dimethylformamide, dimethylsulfoxide, sulpholane.
  • the solvent mixture is preferably a mixture of acetonitrile, sulpholane and water.
  • condensation reaction is carried out in a solvent mixture containing acetonitrile, water and sulpholane in the ratio 1.0: 1.0: 0.1 to 0.5, preferably in the ratio 1.0: 1.0: 0.25.
  • the solvent ratio is very critical in this condensation step and results in formation of desired isomer predominantly as compared to the prior art process, In addition, complete conversion of the reactants occurs, thereby resulting in formation of fewer amounts of impurities.
  • the process thus requires fewer purification steps to get desired quality and yield of 2-Chloro-3-[4-(4-chlorophenyl) cy clohexyl] [ 1 ,4]naphthoquinone .
  • the alkali earth metal hydroxide employed in the hydrolysis reaction is selected from sodium hydroxide, potassium hydroxide and preferably potassium hydroxide.
  • the solvent employed in the hydrolysis step is preferably a mixture of water and alcohol, wherein the alcohol is selected from methanol, ethanol or isopropyl alcohol, preferably methanol.
  • 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4] naphthoquinone compound of formula-IV is subjected to further purification employing a solvent.
  • the solvent is selected from the group comprising alcohol, chlorinated hydrocarbons or mixtures thereof.
  • the alcohol solvent is selected from methanol, ethanol, and isopropyl alcohol.
  • the chlorinated hydrocarbon is selected from dichloromethane, dichloroethane, chloroform.
  • the purified 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l ,4]naphthoquinone contains the desired isomer and impurities within limits.
  • the purified 2-Chloro-3-[4- (4-chlorophenyl)cyclohexy I][1, 4] naphthoquinone is subjected to hydrolysis in the presence of alkali earth metal hydroxides in a solvent to give 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone of compound formula (I).
  • the above isolated 2-[4-(4- chlorophenyl)cyclohexyl]-3-hydroxy-l,4-naphthoquinone of compound formula (I) is further purified in a suitable solvent, preferably acetonitrile to give pure 2-[4-(4- chlorophenyl)cy clohexyl] -3 -hydroxy- 1,4- naphthoquinone of compound formula (I).
  • the pure 2-[4-(4-chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone so obtained is having the purity more than 99.0%, preferably more than 99.5% and all the impurities less than 0.1%.
  • the disclosed process provides good conversion of reactants and formation of fewer impurities, thereby yielding the 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone with high purity.
  • fewer purification steps are required to obtain pure crystalline form of 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone.
  • 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1,4- naphthoquinone obtained is having purity more than 99.0% and all the impurities less than 0.1%.
  • Example- 1 illustrate specific embodiments of the present invention. They are, not intended to be limiting the scope of present invention in any way.
  • Example- 1 illustrate specific embodiments of the present invention. They are, not intended to be limiting the scope of present invention in any way.
  • the toluene layer washed with 10% sodium chloride solution (1000ml X 2) and toluene was removed by distillation completely under vacuum.
  • Acetonitrile (1000 ml) was added to the obtained residue, heated to reflux for over 15- 30 min and cooled to 25 0 C.
  • the solid was filtered and washed with acetonitrile (100ml X 2).
  • Dichloromethane (500ml) was added to the obtained wet material, stirred and methanol (750ml) was added.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed herein discloses a crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone and process for preparing the same and use thereof. The present invention also provides a process for producing 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone employing the crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone to obtain pure and better yield.

Description

CRYSTALLINE FORM OF 2-CHLORO-3-[4-(4-CHLOROPHENYL)
CYCLOHEXYL] [1, ^NAPHTHOQUINONE, PROCESS FOR THE SAME AND
USE FOR PRODUCING 2-[4-(4-CHLOROPHENYL)CYCLOHEXYL]-S-
H YDROX Y- 1,4- NAPHTHOQUINONE
Field of the Invention
This invention, in general relates to a process for producing 2-[4-(4- chlorophenyl) cyclohexyl]-3-hydroxy-l,4-naphthoquinone (Atovaquone). More particularly the present invention provides a crystalline form of 2-chloro-3-[4-(4- chlorophenyl) cyclohexyl] [l,4]naphthoquinone, process for preparing the same and employing the same for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone.
Background of the Invention
Atovaquone is an antiprotozoal agent for oral administration, chemically known as trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4-naphthalenedione as represented by Formula I:
Figure imgf000002_0001
Atovaquone is a unique naphthoquinone with broad-spectrum antiprotozoal activity. It is effective for the treatment and prevention of Pneumocystis carinii pneumonia (PCP), a common parasitic lung infection of immunocompromised patients. It is not only used for the treatment of PCP, but also displays potent activity as an antimalarial agent, and has been used in the treatment of taxoplasmosis and babesiosis. Atovaquone is marketed under the brand name of MEPRON® oral suspension containing about 750mg of Atovaquone.
Atovaquone and its pharmaceutically acceptable salts are first disclosed in US Patent No 5,053,432 (the '432 patent). The patent further discloses a process for the preparation of trans compound of atovaquone. The specific process for the preparation of atovaquone is schematically represented in scheme-I as follows:
Scheme-I
Figure imgf000003_0001
Boiling Methanol
Hydrolysis Sol'n ofKOH/H2O Step-II Cone HCl
RC in Acetonitrile
Figure imgf000003_0002
Formula -I
The '432 patent discloses the process for the preparation of atovaquone, wherein 2-chloro-l,4-naphthoquinone of formula-II is condensed with 4-(4- chlorophenyl)cyclohexane-l-carboxylic acid of formula-Ill in the presence of silver nitrate and ammonium persulphate in a mixture of acetonitrile, sulpholane and water solvent system in the ratio of 1.0: 3.0: 8.0 to give 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4]naphthoquinone compound of formula-IV which is further subjected to hydrolysis in the presence of boiling methanol and aqueous KOH followed by recrystallization in acetonitrile to give atovaquone of compound of formula-I.
US Patent No 4,981,874 (the '874 patent) discloses a process for the preparation of atovaquone, wherein 2-chloro-l,4-naphthoquinone of formula-II is condensed with 4-(4-chlorophenyl)cyclohexane-l-carboxylic acid of formula-Ill in the presence of silver nitrate in a mixture of acetonitrile and water solvent system in the ratio of 5.0:6.0 to give 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone compound of formula-IV which is further subjected to hydrolysis in the presence of boiling methanol and aqueous KOH followed by recrystallization in acetonitrile to give atovaquone compound of formula-I.
In the prior art processes 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone is obtained in low yield less than about 37%. In addition, the process requires a number of purification steps in different solvent mixtures to give the desired quality of the product.
Hence, the existing processes produce atovaquone having low purity and involve tedious ' work up to isolate the required product. A large number of purification steps result in low yield of the final product and makes the process more time consuming and not viable for commercial scale up.
Tetrahedron Letters 39 (1998) 7629-7632 discloses a process for the preparation of atovaquone which is schematically represented in scheme-H as follows:
Scheme-II
Figure imgf000004_0001
According to the above scheme, the process for the preparation of atovaquone includes condensing 2-chloro-l,4-naphthoquinone compound of formula-II with 4-(4- chlorophenyl)cyclohexane-oxalate acid compound of formula- V in the presence of the phase transfer catalyst Adogen®464, oxidant ammonium persulphate in a mixture of dichloromethane, acetonitrile and water in the ratio of 1:1:2 to give 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4] naphthoquinone in 43% yield and an additional side product with 38% yield. Subsequently, 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4] naphthoquinone is converted to atovaquone upon treatment with potassium hydroxide in methanol at reflux followed by recrystallization Jn hot acetonitrile.
The additional side product formed along with the compound of formula-I in the process requires repeated crystallizations to remove the additional side product from the final product, thereby resulting in low yield at final stage.
In light of the foregoing processes, there exists a need to develop an alternate, simple and commercially viable process for producing atovaquone. In addition, the process should produce fewer side products thereby requiring fewer purification steps and resulting in high yield of the final product. Objects and Summary of the Invention
It is an object of the present invention to provide a crystalline form of 2- chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone and process thereof.
It is another object of the present invention to provide an improved process for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l ,4- naphthoquinone employing the crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [ 1 ,4]naphthoquinone.
It is yet another object of the present invention to provide a cost effective, commercially viable and easily scalable process for producing 2-[4-(4- chlorophenyl)cyclohexyl]-3-hydroxy- 1 ,4- naphthoquinone. It is still another object of the present invention to provide an improved process for the preparation of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone, wherein the process produces fewer side products and requires minimal purification steps to obtain 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone with high purity. The above and other objects of the present invention are further attained and supported by the following embodiments described herein. However, the scope of the invention is not restricted to the described embodiments herein after. In accordance with one preferred embodiment of the present invention, there is provided a crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein said crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by an X-ray powder diffraction pattern having peaks at about 7.14, 9.91, 14.45, 14.90, 16.23, 17.81, 19.93, 21.56, 25.23, 25.51, 26.74 ± 0.2 θ°.
In accordance with another embodiment of the present invention, there is provided a compound 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone prepared by hydrolyzing the 2-Chloro-3-[4J?(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone in the presence of an alkali earth metal hydroxide and a solvent to give 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone , wherein the 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone is characterized by having purity more than 99.0%, preferably more than 99.5%. In accordance with another embodiment of the present invention, there is provided a process for preparing crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein the process comprises of condensing 2- chloro-[l,4] naphthoquinone with 4-(4-chlorophenyl)-cyclohexane carboxylic acid in the presence of silver nitrate and a persulphate in a solvent mixture to give 2-Chloro- 3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein the solvent mixture comprises acetonitrile, water and sulpholane in the ratio of 1.0: 1.0: 0.1 to 0.5.
In accordance with still another embodiment of the present invention, wherein the process further comprises of purifying the 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone by employing a solvent to obtain pure crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone.
In accordance with still another embodiment of the present invention, there is provided a process for preparing 2-[4-(4-chlorophenyl) cyclohexy 1] -3 -hydroxy- 1,4- naphthoquinone, the process comprises of condensing 2-chloro-[l,4] naphthoquinone with 4-(4-chlorophenyl)-cyclohexane carboxylic acid in the presence of silver nitrate and a persulphate in a solvent mixture to give 2-Chloro-3-[4-(4- chlorophenyl) cyclohexy I][1, 4] naphthoquinone, and hydrolyzing the 2-Chloro-3-[4- (4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone in the presence of an alkali earth metal hydroxide and a solvent to give 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1,4- naphthoquinone, wherein the solvent mixture used for the condensation comprises acetonitrile, water and sulpholane in the ratio 1.0: 1.0: 0.1 to 0.5.
In accordance with yet another embodiment of the present invention, the solvent used in hydrolyzing the 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is mixture of water and alcohol. The alcohol solvent is selected from methanol, ethanol and isopropyl alcohol, preferably methanol.
In accordance with still another embodiment of the present invention, wherein the process further comprises of purifying the 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone employing a solvent to obtain pure 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone.
In accordance with still another embodiment of the present invention, wherein the process further comprises of micronizing the pure 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone to obtain micronized 2- [4- (4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone having particle size distribution dg0 less than 10 micrometer, preferably between 3.0 - 10 micrometer. i Brief Description of the Drawings
Further objects of the present invention together with additional features contributing thereto and advantages accruing there from will be apparent from the following description of preferred embodiments of the invention which are shown in the accompanying drawing figures, wherein:
Fig. 1 . shows the X-ray diffraction pattern of 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone (Atovaquone) obtained as per the present invention. Fig. 2 shows the X-ray diffraction pattern of 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl] [l,4]naphthoquinone compound of formula-IV obtained as per the present invention.
Detailed Description of the Invention
While this specification concludes with claims particularly pointing out and distinctly claiming that, which is regarded as the invention, it is anticipated that the invention can be more readily understood through reading the following detailed description of the invention and study of the included examples. The present invention discloses a crystalline form of 2-chloro-3-[4-(4- chlorophenyl) cyclohexyl] [l,4]naphthoquinone. The crystalline form of 2-chloro-3- [4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by X-ray powder diffraction pattern. Further, the present invention describes an improved process for the preparation of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone. In addition, the 2,-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is employed for the preparation of 2- [4-(4-chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone. Powder X-rav Diffraction (PXRDI
The crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone of the present invention is characterized by its X-ray powder diffraction pattern. Thus, the X-ray diffraction pattern of said crystalline form of the invention was measured on PANaiytical, X'Pert PRO powder diffractometer equipped with goniometer of θ/θ configuration and X'Celerator detector. The Cu-anode X-ray tube was operated at 40 KV and 30 mA. The experiments were conducted over the 2Θ range of 2.0°-50.0°, 0.030° step size and 50 seconds step time.
The crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by an X-ray powder diffraction pattern as shown in Figure 2 having peaks at about 7.14, 9.91, 14.45, 14.90, 16.23, 17.81, 19.93, 21.56, 25.23, 25.51, 26.74 ± 0.2 θ°.
According to the present invention, the improved process for the preparation of crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone of formula IV, wherein the process involves condensing 2- chloro-[ 1,4] naphthoquinone of formula (III) with 4-(4-chlorophenyl)-cyclohexane carboxylic acid of formula (II) in the presence of free radical initiators and an oxidant in a solvent mixture to give crude 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4]naphthoquinone of formula (IV) as shown in the following scheme: Scheme-Ill
Figure imgf000009_0001
According to the present invention, the process further comprises hydrolyzing 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4]naphthoquinone using an alkali earth metal hydroxide in presence of a suitable solvent to give 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone of formula I.
According to the present invention, the free radical initiator used in the condensation reaction is selected from sodium persulphate, ammonium persulphate, more preferably sodium persulphate and the oxidant is preferably silver nitrate.
According to the present invention, the solvent mixture used in the condensation of 2-chloro-[l,4]naphthoquinone of Formula-Ill with 4-(4- chlorophenyl)-cyclohexane carboxylic acid of Formula-II to obtain 2-Chloro-3-[4-(4- chlorophenyl) cyclohexyl][l,4]naphthoquinone compound of formula- IV is selected from water miscible organic solvent, water or mixtures thereof. The water miscible organic solvent is selected from acetonitrile, acetone, dimethylformamide, dimethylsulfoxide, sulpholane. The solvent mixture is preferably a mixture of acetonitrile, sulpholane and water.
According to a preferred embodiment of the present invention, condensation reaction is carried out in a solvent mixture containing acetonitrile, water and sulpholane in the ratio 1.0: 1.0: 0.1 to 0.5, preferably in the ratio 1.0: 1.0: 0.25. The solvent ratio is very critical in this condensation step and results in formation of desired isomer predominantly as compared to the prior art process, In addition, complete conversion of the reactants occurs, thereby resulting in formation of fewer amounts of impurities. The process thus requires fewer purification steps to get desired quality and yield of 2-Chloro-3-[4-(4-chlorophenyl) cy clohexyl] [ 1 ,4]naphthoquinone .
According to the present invention, the alkali earth metal hydroxide employed in the hydrolysis reaction is selected from sodium hydroxide, potassium hydroxide and preferably potassium hydroxide. The solvent employed in the hydrolysis step is preferably a mixture of water and alcohol, wherein the alcohol is selected from methanol, ethanol or isopropyl alcohol, preferably methanol.
According to the present invention, 2-Chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4] naphthoquinone compound of formula-IV is subjected to further purification employing a solvent. The solvent is selected from the group comprising alcohol, chlorinated hydrocarbons or mixtures thereof. The alcohol solvent is selected from methanol, ethanol, and isopropyl alcohol. The chlorinated hydrocarbon is selected from dichloromethane, dichloroethane, chloroform.
The purified 2-Chloro-3-[4-(4-chlorophenyl)cyclohexyl][l ,4]naphthoquinone contains the desired isomer and impurities within limits. The purified 2-Chloro-3-[4- (4-chlorophenyl)cyclohexy I][1, 4] naphthoquinone is subjected to hydrolysis in the presence of alkali earth metal hydroxides in a solvent to give 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone of compound formula (I).
According to the present invention, the above isolated 2-[4-(4- chlorophenyl)cyclohexyl]-3-hydroxy-l,4-naphthoquinone of compound formula (I) is further purified in a suitable solvent, preferably acetonitrile to give pure 2-[4-(4- chlorophenyl)cy clohexyl] -3 -hydroxy- 1,4- naphthoquinone of compound formula (I). The pure 2-[4-(4-chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone so obtained is having the purity more than 99.0%, preferably more than 99.5% and all the impurities less than 0.1%. USP reference standard material and 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1 ,4-naphthoquinone obtained by the present invention were analyzed by HPLC. According to the present invention, 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy-l,4-naphthoquinone is subjected to micronization to get a particle size distribution with dc>o less than 10.0 micrometer, preferably more than 3.0 micrometer, more preferably dgo between 4.0 to 6.0 micrometer. The disclosed process provides good conversion of reactants and formation of fewer impurities, thereby yielding the 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone with high purity. In addition fewer purification steps are required to obtain pure crystalline form of 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone. Furthermore, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1,4- naphthoquinone obtained is having purity more than 99.0% and all the impurities less than 0.1%.
The following non-limiting examples illustrate specific embodiments of the present invention. They are, not intended to be limiting the scope of present invention in any way. Example- 1
Preparation of 2-chloro-3-r4-(4-chlorophenyl)cvclohexyll[l, 4] naphthoquinone compound of Formula-IV
A mixture of 2-chloro-[l,4]naphthoquinone (100.85g), acetonitrile (2000ml), DM water (2000ml), 4-(4-chlorophenyl)-cyclohexane carboxylic acid (10Og), silver nitrate (26.8g) and sulpholane (500ml) was heated to 70-750C. Sodium persulphate solution (500ml) was added to the mixture and the mixture cooled to 250C. Toluene (1000ml) was added to the reaction mass, filtered and the layers were separated. Subsequently, toluene (200ml) was again added to the resulting reaction mass, the layers separated and washed with 10% sodium chloride solution (1000ml X 2). Toluene was distilled off completely under vacuum. Acetonitrile (1000 ml) was added to the obtained residue, heated to reflux for over 15-30 min and cooled to 250C. The solid was filtered and washed with acetonitrile (100ml X 2). Dichloromethane (500ml) was added to the obtained wet material, stirred and methanol (750ml) was added. The solid was filtered, washed with methanol (100ml X 2) and dried under vacuum till LOD is <1.0%w/w to get 2-chloro-3-[4-(4-chlorophenyl)cyclohexyl][l,4] naphthoquinone. Yield: 34g. Example-2
Preparation of 2-chloro-3 - [4-(4-chlorophenyl>)cvclohexyl1 [ 1 ,4] naphthoquinone
To a mixture of 2-chloro-[l,4]naphthoquinone (100.85g), acetonitrile (2000ml), DM water (2000ml), 4-(4-chlorophenyl)-cyclohexanecarboxylic acid (10Og), silver nitrate (26.8g) and sulpholane (500ml). The mixture was heated to 65- 7O0C and sodium persulphate solution is added (247.3 gm 500ml water). The resulting mixture was stirred for 2-3 hrs at 65-7O0C and cooled to 5-1O0C. The resultant mass was filtered and residual sticky solid was extracted with toluene (1500ml) to remove inorganic material. The toluene layer washed with 10% sodium chloride solution (1000ml X 2) and toluene was removed by distillation completely under vacuum. Acetonitrile (1000 ml) was added to the obtained residue, heated to reflux for over 15- 30 min and cooled to 250C. The solid was filtered and washed with acetonitrile (100ml X 2). Dichloromethane (500ml) was added to the obtained wet material, stirred and methanol (750ml) was added. The solid was filtered, washed with methanol (100ml X 2) and dried under vacuum till LOD is <1.0%w/w to get 2-chloro- 3 - [4-(4-chloropheny l)cyclohexyl] [ 1 ,4]naphthoquinone . Yield: 37g.
Example-3 Preparation of 2-[4-(4-chlorophenyl)cvclohexyl]-3-hvdroxy- 1 ,4-naphthoquinone compound of Formula-I (Atovaquone)
To ' a mixture of 2-chloro-3-[4-(4- chlorophenyl)cyclohexyl][l,4]naphthoquinone (10Og) and methanol (1800ml), potassium hydroxide solution (50.97 gm in 900ml) was added and heated to reflux for 300-360 min. The reaction mass was cooled to 250C and toluene (1000ml) was added. The aqueous layer was separated, filtered and washed with methanol: water in the ratio 2:1 (200ml). The pH of the filtrate and washing was adjusted to 5.0-5.5 by HCl solution (~250ml). The solid was filtered and water (1000ml) was added to the wet material. The resultant solid was filtered and washed with water (500ml). Acetonitrile (8500ml) was added to the wet material, heated to reflux for about 30min and slowly cooled to 20-250C. The solid was filtered, washed with acetonitrile (200ml) and dried under vacuum till LOD is <0.5%w/w to get 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy-1,4- naphthoquinone. Yield: 75g.
HPLC analysis for various samples obtained using the above mentioned process was performed, the results of which are mentioned in Table 1.
Table 1
Figure imgf000013_0001
Example-4
Micronization of 2-r4-(4-chlorophenvDcvclohexyl1-3-hvdroxy- 1 ,4-naphthoquinone 2-r4-(4-chlorophenyl)cyclohexyl~|-3-hvdroxy- 1 ,4-naphthoquinone was micronized to obtain a target d9o between lOμm to 3μm. The particle size obtained in the above examples dso (0.5) of the feed stock was 25.45μm with a d90(0.9) of 52.58μm. This was micronized and material produced with partial size dso(O.5) of 1.9μm with a d9o(O.9) of 4.4μm.
Certain modifications and improvements of the disclosed invention will occur to those skilled in the art without departing from the scope of invention, which is limited only by the appended claims.

Claims

We Claim:-
1. A crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein said crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by an X-ray powder diffraction pattern having peaks at about 7.14, 9.91, 14.45, 14.90, 16.23, 17.81, 19.93, 21.56, 25.23, 25.51, 26.74 ± 0.2 θ°
2. The crystalline form according to claim 1, wherein said crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is having a substantially similar X-ray powder diffraction pattern as depicted in Figure 2.
3. The crystalline form according to claim 1, wherein said crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is employed to prepare 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1,4- naphthoquinone by hydrolyzing the 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone in the presence of an alkali earth metal hydroxide and a solvent to give 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1 ,4- naphthoquinone.
4. The crystalline form according to claim 3, wherein the solvent is a mixture of water and alcohol.
5. The crystalline form according to claim 1, wherein said crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone is characterized by having purity more than 99.0%, preferably more than 99.5%.
6. A process for preparing crystalline form of 2-Chloro-3-[4-(4- chlorophenyl) cyclohexyl] [1,4] naphthoquinone comprising condensing 2-chloro- [1,4] naphthoquinone with 4-(4-chlorophenyl)-cyclohexane carboxylic acid in the presence of silver nitrate and a persulphate in a solvent mixture to give 2-Chloro-3-[4- (4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein the solvent mixture comprises acetonitrile, water and sulpholane in the ratio of 1.0: 1.0: 0.1 to 0.5.
7. The process according to claim 6, wherein the ratio of acetonitrile, water and sulpholane in the solvent mixture is 1.0: 1.0: 0.1 to 0.25.
8. The process according to claim 6, wherein the persulphate is selected from ammonium persulphate or sodium persulphate.
,
9. The process according to claim 6, wherein the process further comprising purifying 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone by employing a solvent to obtain pure crystalline form of 2- Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone.
10. The process according to claim 9, wherein the solvent is selected from a group comprising alcohol, chlorinated solvents or mixtures thereof.
11. The process according to claim 10, wherein the alcohol is selected from methanol, ethanol and isopropyl alcohol.
12. The process according to claim 10, wherein the chlorinated solvent is selected from diςhloromethane, dichloroethane or mixtures thereof.
13. A process for preparing 2-[4-(4-chlorophenyl) cyclohexyl] -3 -hydroxy- 1 ,4- naphthoquinone, the process comprising: a) condensing 2-chloro-[l,4] naphthoquinone with 4-(4- chlorophenyl)-cyclohexane carboxylic acid in the presence of silver nitrate and a persulphate in a solvent mixture to give 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone, wherein the solvent mixture comprises acetonitrile, water and sulpholane in the ratio 1.0: 1.0: 0.1 to 0.5; and b) hydrolyzing the 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4] naphthoquinone in the presence of an alkali earth metal hydroxide and a solvent to give 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1 ,4- naphthoquinone.
14. The process according to claim 13, wherein the ratio of acetonitrile, water and sulpholane in the solvent mixture is 1.0: 1.0: 0.1 to 0.25.
15. The process according to claim 13, wherein the persulphate is selected from ammonium persulphate or sodium persulphate.
16. The crystalline form according to claim 13, wherein the solvent employed in step (b) is a mixture of water and alcohol.
17. The process according to claim 13, the process further comprising purifying 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l ,4- naphthoquinone employing a solvent to obtain pure 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone..
18. The process according to claim 17, wherein the solvent is preferably acetonitrile.
19. The process according to claim 17, wherein the process further comprising micronizing the pure 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone to obtain micronized 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy- 1,4- naphthoquinone having particle size distribution d9o less than 10 micrometer, preferably between 3.0 - 10 micrometer.
20. A compound 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-l,4- naphthoquinone prepared according to claim 13, wherein the 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone is characterized by having purity more than 99.0% and preferably more than 99.5%.
PCT/IN2009/000462 2008-08-29 2009-08-20 Crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4]naphthoquinone, process for the same and use for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone WO2010023686A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2120/CHE/2008 2008-08-29
IN2120CH2008 2008-08-29

Publications (2)

Publication Number Publication Date
WO2010023686A2 true WO2010023686A2 (en) 2010-03-04
WO2010023686A3 WO2010023686A3 (en) 2010-08-12

Family

ID=41722048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000462 WO2010023686A2 (en) 2008-08-29 2009-08-20 Crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4]naphthoquinone, process for the same and use for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone

Country Status (1)

Country Link
WO (1) WO2010023686A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098832A2 (en) 2011-09-08 2013-07-04 Dishman Pharmaceuticals & Chemicals Ltd. Novel process for selective isolation and purification of 2-[4-(4-chlorophenyl) cyclohexyl]-3-chloro-1, 4-naphthoquinone and atovaquone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004021A1 (en) * 1989-09-22 1991-04-04 The Wellcome Foundation Limited Medicaments for the treatment of toxoplasmosis
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
WO1991004021A1 (en) * 1989-09-22 1991-04-04 The Wellcome Foundation Limited Medicaments for the treatment of toxoplasmosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098832A2 (en) 2011-09-08 2013-07-04 Dishman Pharmaceuticals & Chemicals Ltd. Novel process for selective isolation and purification of 2-[4-(4-chlorophenyl) cyclohexyl]-3-chloro-1, 4-naphthoquinone and atovaquone
WO2013098832A3 (en) * 2011-09-08 2013-10-10 Dishman Pharmaceuticals & Chemicals Ltd. Novel process for selective isolation and purification of 2-[4-(4-chlorophenyl) cyclohexyl]-3-chloro-1, 4-naphthoquinone and atovaquone

Also Published As

Publication number Publication date
WO2010023686A3 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
JP5535082B2 (en) Method for synthesizing bosentan, polymorphic forms thereof and salts thereof
US20170355666A1 (en) Polymorphs of cddo ethyl ester and uses thereof
US20100081847A1 (en) New process for preparation of atovaquone and novel intermediates thereof
WO2009057140A2 (en) Improved process for memantine hydrochloride
WO2011128911A2 (en) Improved process for ll-[(z)-3-(dimethylamino)propyiidenel-6-ll- dihydrodibenz[b,el oxepin-2-aceticacid
WO2010023686A2 (en) Crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4]naphthoquinone, process for the same and use for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3- hydroxy- 1,4- naphthoquinone
JPH08504830A (en) Spirostanil glycoside crystalline monohydrate
WO2011158249A1 (en) Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran
NL8101067A (en) ACYL DERIVATIVES OF CARNITINE, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES.
US10633337B2 (en) Crystal forms of a 9-aminomethyl substituted tetracycline compound and a preparation method thereof
DD262426A1 (en) PROCESS FOR PREPARING NEW SALTS OF ARYLOXYPROPANOLAMINES WITH DIPHENYL ACIDIC ACID
CN112441995A (en) Purification method of propranolol hydrochloride key intermediate
EP2467358B1 (en) Novel complex for treatment and/or prophylaxis of parasitic infections
WO2009153806A2 (en) Process for preparing memantine hydrochloride substantially free of !mpurities
WO2009001367A2 (en) Novel crystalline forms of atovaquone
WO2003087041A1 (en) Continuous process for the manufacture of 3-hydroxy propionitrile
RU2819168C1 (en) Method of producing benzyl benzoate
US20100137632A1 (en) Process for oseltamivir phosphate
CN115850220B (en) Stable amiodarone hydrochloride, preparation method and application thereof
WO2006035295A1 (en) Process for the purification of lovastatin
EP2555616A1 (en) Process for the preparation of memantine hydrochloride
US20120178821A1 (en) Polymorphic form of toremifene citrate and process for its preparation
WO2007096904A2 (en) Improved process for the preparation of terbinafine hydrochloride and novel crystalline form of terbinafine
JPS62238238A (en) Butenoic acid derivative
WO2020075024A1 (en) Process for preparation of memantine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09809428

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09809428

Country of ref document: EP

Kind code of ref document: A2